Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visualizing beta cells in patients with a history of gestational diabetes
2016-000794-20Phase 2Active
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2016
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of 68Ga-NODAGA-Exendin-4 in gestational diabetes mellitus (GDM) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Pancreatic 68Ga-NODAGA-exendin-4 uptake. Started Aug 2016; status: active.
02
Drugs
68Ga-NODAGA-Exendin-4
03
Conditions
gestational diabetes mellitus (GDM)
Beyond the preview
Go deeper on 2016-000794-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000794-20.